Current taxane formulations and emerging cabazitaxel delivery systems

Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.

[1]  Wentao Song,et al.  Therapeutic surfactant-stripped frozen micelles , 2016, Nature Communications.

[2]  Baorui Liu,et al.  Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[3]  R. Arceci,et al.  Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Klumperman,et al.  Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate) as a drug delivery vehicle for hydrophobic drugs. , 2012, Biomacromolecules.

[5]  E. Rowinsky.  Paclitaxel pharmacology and other tumor types. , 1997, Seminars in oncology.

[6]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[7]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[8]  D. Bruns,et al.  Oxidation of polyethylene glycols by alcohol dehydrogenase. , 1989, Biochemical pharmacology.

[9]  Jung Wan Hong,et al.  Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy , 2012 .

[10]  Jaroslav Turánek,et al.  Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[11]  R. Kim,et al.  Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. , 2003, Molecular cancer therapeutics.

[12]  Z. Duan,et al.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.

[13]  P. Chacón,et al.  Changes in Microtubule Protofilament Number Induced by Taxol Binding to an Easily Accessible Site , 1998, The Journal of Biological Chemistry.

[14]  Supriya Shidhaye,et al.  Advances in polymeric micelles for drug delivery and tumor targeting. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[15]  J. Vishwanatha,et al.  Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain , 2017, Nanomedicine.

[16]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[17]  J. Verweij,et al.  Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[19]  Ventola Cl,et al.  Progress in Nanomedicine: Approved and Investigational Nanodrugs. , 2017 .

[20]  D. Bourissou,et al.  Y-shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core-corona nanoparticles. , 2013, Biomacromolecules.

[21]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[22]  D. Leeper,et al.  Extracellular pH distribution in human tumours. , 1995, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[23]  E. Antonarakis,et al.  Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer , 2011, Drug design, development and therapy.

[24]  M. Millward,et al.  Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide , 1997, Cancer Chemotherapy and Pharmacology.

[25]  S. Nicoll,et al.  Characterization of novel photocrosslinked carboxymethylcellulose hydrogels for encapsulation of nucleus pulposus cells. , 2010, Acta biomaterialia.

[26]  P. Vrignaud,et al.  Preclinical profile of cabazitaxel , 2014, Drug design, development and therapy.

[27]  Dong-Wan Kim,et al.  Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Fishman,et al.  Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel , 2008, Clinical Cancer Research.

[29]  Junyang Wang,et al.  Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer , 2016, International journal of nanomedicine.

[30]  A. Hoenger,et al.  Structural rearrangements in tubulin following microtubule formation , 2005, EMBO reports.

[31]  P. Hwu,et al.  Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma , 2010, Melanoma research.

[32]  P. Vrignaud,et al.  Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors , 2013, Clinical Cancer Research.

[33]  Sung-Bae Kim,et al.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[34]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Xing Tang,et al.  Evaluation of the stability and pharmacokinetics of cabazitaxel‐loaded intravenous lipid microspheres: Beneficial effect of cholesterol , 2015 .

[36]  S. Boorjian,et al.  Overcoming Drug Resistance and Treating Advanced Prostate Cancer , 2012, Current drug targets.

[37]  N. Zhang,et al.  Redox-Sensitive Citronellol-Cabazitaxel Conjugate: Maintained in Vitro Cytotoxicity and Self-Assembled as Multifunctional Nanomedicine. , 2016, Bioconjugate chemistry.

[38]  D. Ferry,et al.  A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma , 2008, Cancer Chemotherapy and Pharmacology.

[39]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[40]  P. Vrignaud,et al.  Novel Taxanes: Cabazitaxel Case Study , 2012 .

[41]  Triantafyllos Stylianopoulos,et al.  Design considerations for nanotherapeutics in oncology. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[42]  J. Griffiths,et al.  Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous 19F and 31P probes , 1999, NMR in biomedicine.

[43]  E. Eisenhauer,et al.  An overview of phase II studies of docetaxel in patients with metastatic breast cancer. , 1995, European journal of cancer.

[44]  F M Muggia,et al.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.

[45]  Lin Mei,et al.  Paclitaxel drug delivery systems , 2013, Expert opinion on drug delivery.

[46]  J. Beijnen,et al.  Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel , 1999 .

[47]  Yoshio Hayashi,et al.  Paclitaxel prodrugs: toward smarter delivery of anticancer agents. , 2006, Journal of medicinal chemistry.

[48]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Lovell,et al.  Mechanisms of light‐induced liposome permeabilization , 2016, Bioengineering & translational medicine.

[50]  J. Verweij,et al.  Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[51]  V. Torchilin,et al.  New Developments in Liposomal Drug Delivery. , 2015, Chemical reviews.

[52]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Kessel,et al.  Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. , 1994, British Journal of Cancer.

[54]  R. A. Jain,et al.  The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.

[55]  Bryan Hoang,et al.  Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. , 2017, Cancer letters.

[56]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[57]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[58]  M. Mirjalili,et al.  Biotechnological production of taxol and related taxoids: current state and prospects. , 2009, Anti-cancer agents in medicinal chemistry.

[59]  W. Hennink,et al.  Reduction-sensitive polymers and bioconjugates for biomedical applications. , 2009, Biomaterials.

[60]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[61]  Hasan Toǧrul.  Production of carboxymethyl cellulose from sugar beet pulp cellulose and rheological behaviour of carboxymethyl cellulose , 2003 .

[62]  Natarajan Raghunand,et al.  In vivo imaging of extracellular pH using 1H MRSI , 1999, Magnetic resonance in medicine.

[63]  Jian Li,et al.  Exploiting sequence to control the hydrolysis behavior of biodegradable PLGA copolymers. , 2011, Journal of the American Chemical Society.

[64]  R. Straubinger,et al.  Novel Taxol formulations: Taxol-containing liposomes. , 1993, Journal of the National Cancer Institute. Monographs.

[65]  M. Untch,et al.  Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. , 1994, Anti-cancer drugs.

[66]  Derek S. Chan,et al.  SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice , 2013, Gut.

[67]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[68]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[69]  C. L. Ventola,et al.  Progress in Nanomedicine: Approved and Investigational Nanodrugs. , 2017, P & T : a peer-reviewed journal for formulary management.

[70]  M. Zaworotko,et al.  Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. , 2003, International journal of pharmaceutics.

[71]  J. Lovell,et al.  Advanced Functional Nanomaterials for Theranostics , 2017, Advanced functional materials.

[72]  E. Nogales,et al.  Crystallographic structure of tubulin: implications for dynamics and drug binding. , 1999, Cell structure and function.

[73]  D. Guénard,et al.  Taxol and taxotere: discovery, chemistry, and structure-activity relationships , 1993 .

[74]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Yaling Shen,et al.  A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time , 2016, Journal of biomaterials science. Polymer edition.

[76]  David J Newman,et al.  A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. , 2004, Journal of natural products.

[77]  M. Ellis,et al.  Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies , 2009, Cancer Chemotherapy and Pharmacology.

[78]  J. Díaz,et al.  Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. , 1993, Biochemistry.

[79]  Hao Shen,et al.  An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth , 2003, Cancer biology & therapy.

[80]  J. Szebeni,et al.  Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[81]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[82]  M. Ghahremani,et al.  Peptide functionalized poly ethylene glycol-poly caprolactone nanomicelles for specific cabazitaxel delivery to metastatic breast cancer cells. , 2017, Materials science & engineering. C, Materials for biological applications.

[83]  J. Schellens,et al.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.

[84]  Youmei Feng,et al.  Cellular uptake and intracellular trafficking of PEG-b-PLA polymeric micelles. , 2012, Biomaterials.

[85]  Shyh-Dar Li,et al.  A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[86]  A. Gown,et al.  Distribution of SPARC in normal and neoplastic human tissue. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[87]  Rassoul Dinarvand,et al.  PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. , 2008, International journal of pharmaceutics.

[88]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[89]  E. Atkinson,et al.  Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Ravi Kumar,et al.  Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study , 2016, Breast Cancer Research and Treatment.

[91]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[92]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  Xing Tang,et al.  Improving cabazitaxel chemical stability in parenteral lipid emulsions using cholesterol. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[94]  Gordon M. Cragg.  Paclitaxel (Taxol®): A success story with valuable lessons for natural product drug discovery and development , 1998, Medicinal research reviews.

[95]  J Verweij,et al.  Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients , 2000, Anti-cancer drugs.

[96]  G. E. Atilla‐Gokcumen,et al.  Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes , 2017, Molecular Cancer Therapeutics.

[97]  Shyh-Dar Li,et al.  Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. , 2012, Biomaterials.

[98]  Wim E Hennink,et al.  Cancer nanomedicines: oversold or underappreciated? , 2017, Expert opinion on drug delivery.

[99]  Jianwen Liu,et al.  Glutathione-responsive core cross-linked micelles for controlled cabazitaxel delivery , 2018, Journal of Nanoparticle Research.

[100]  Simon A McManus,et al.  Using Flash Nanoprecipitation To Produce Highly Potent and Stable Cellax Nanoparticles from Amphiphilic Polymers Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel. , 2017, Molecular pharmaceutics.

[101]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[102]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[103]  J. Watkins,et al.  Suspected anaphylactic reaction to Cremophor EL. , 1980, British medical journal.

[104]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[105]  F. Schacher,et al.  Functional block copolymers: nanostructured materials with emerging applications. , 2012, Angewandte Chemie.

[106]  C. Van de Wiele,et al.  Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. , 2008, Current pharmaceutical design.

[107]  M. Dellian,et al.  Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer , 2010, International journal of cancer.

[108]  D. Jäger,et al.  Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[109]  W. Gradishar,et al.  Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  M. A. Gotardo,et al.  Migration of diethylhexyl phthalate from PVC bags into intravenous cyclosporine solutions. , 2005, Journal of pharmaceutical and biomedical analysis.

[111]  S. Feng,et al.  Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[112]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[113]  Xinrong Liu,et al.  Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system , 2014, International journal of nanomedicine.

[114]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[116]  G. Hortobagyi,et al.  Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.

[117]  J. Chern,et al.  Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. , 1999, Bioconjugate chemistry.

[118]  J. Verweij,et al.  Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[120]  Jun Xia,et al.  Surfactant‐Stripped Frozen Pheophytin Micelles for Multimodal Gut Imaging , 2016, Advanced materials.

[121]  J. Arezzo,et al.  Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. , 2008, Clinical advances in hematology & oncology : H&O.

[122]  Docetaxel Nanotechnology in Anticancer Therapy , 2012, ChemMedChem.

[123]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .

[124]  Qian Zhang,et al.  A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[125]  Dandan Luo,et al.  Nanomedical engineering: shaping future nanomedicines. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[126]  E. Abadie,et al.  The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. , 2012, The oncologist.

[127]  H. Rosing,et al.  Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. , 2013, Clinical therapeutics.

[128]  M. Büchert,et al.  Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  Norased Nasongkla,et al.  Functionalized Micellar Systems for Cancer Targeted Drug Delivery , 2007, Pharmaceutical Research.

[130]  Yating Sun,et al.  Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel. , 2017, Anti-cancer agents in medicinal chemistry.

[131]  Chen Xie,et al.  Drug-loaded pseudo-block copolymer micelles with a multi-armed star polymer as the micellar exterior. , 2015, Nanoscale.

[132]  Guping Tang,et al.  Poly(N-vinylpyrrolidinone) microgels: preparation, biocompatibility, and potential application as drug carriers. , 2014, Biomacromolecules.

[133]  M. Ellis,et al.  Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. , 2009, Cancer chemotherapy and pharmacology.

[134]  J. Zhang,et al.  Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[135]  C. S. Giam,et al.  Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. , 1986, American journal of hospital pharmacy.

[136]  Robert J. Lee,et al.  Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel. , 2016, Anticancer research.

[137]  I. Barasoain,et al.  Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. , 2003, Current cancer drug targets.

[138]  Gert Storm,et al.  Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.

[139]  J. Alderfer,et al.  Solvent- and concentration-dependent molecular interactions of taxol (Paclitaxel). , 1994, Journal of pharmaceutical sciences.

[140]  P. Bornstein,et al.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.

[141]  Shuli Wang,et al.  Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system , 2016, Drug development and industrial pharmacy.

[142]  G. Storm,et al.  The battle of “nano” paclitaxel , 2017, Advanced drug delivery reviews.

[143]  Jianping Qi,et al.  Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. , 2012, Current drug metabolism.

[144]  K. Tkaczuk,et al.  Update on taxane development: new analogs and new formulations , 2012, Drug design, development and therapy.

[145]  R. Garlick,et al.  The principal site of nonenzymatic glycosylation of human serum albumin in vivo. , 1983, The Journal of biological chemistry.

[146]  Afsaneh Lavasanifar,et al.  Amphiphilic block copolymers for drug delivery. , 2003, Journal of pharmaceutical sciences.

[147]  Tae Won Kim,et al.  A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel , 2013, Investigational New Drugs.

[148]  G. Nightingale,et al.  Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. , 2012, P & T : a peer-reviewed journal for formulary management.

[149]  C. Yuan,et al.  Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials , 2017, Nanotheranostics.

[150]  R. B. Campbell,et al.  Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. , 2001, Journal of pharmaceutical sciences.

[151]  Zhirong Zhang,et al.  Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity , 2017, Journal of drug targeting.

[152]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[153]  D. Jäger,et al.  Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. , 2012 .

[154]  Robert J. Griffin,et al.  Indocyanine green enhanced near‐infrared laser treatment of murine mammary carcinoma , 2012, International journal of cancer.

[155]  Zhe-Sheng Chen,et al.  Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10) , 2004, Cancer Research.

[156]  H. Ueno,et al.  A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation , 2007, British Journal of Cancer.

[157]  J. Verweij,et al.  Alternative drug formulations of docetaxel: a review. , 2007, Anti-cancer drugs.

[158]  Jung Wan Hong,et al.  Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation , 2007, Molecular Cancer Therapeutics.

[159]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[160]  Felix Kratz,et al.  A clinical update of using albumin as a drug vehicle - a commentary. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[161]  Chunqi Zhu,et al.  Enhanced antitumor activity of cabazitaxel targeting CD44+ receptor in breast cancer cell line via surface functionalized lipid nanocarriers , 2017 .

[162]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[163]  Marie-Hélène Dufresne,et al.  Block copolymer micelles: preparation, characterization and application in drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[164]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[165]  H. Brem,et al.  Paclitaxel: a review of adverse toxicities and novel delivery strategies , 2007, Expert opinion on drug safety.

[166]  F. Atyabi,et al.  Targeted Delivery of Cabazitaxel by Conjugation to Albumin-PEG-folate Nanoparticles Using a Cysteine-acrylate Linker and Simple Synthesis Conditions. , 2017, Current drug delivery.

[167]  Xianhuo Wang,et al.  A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. , 2010, European journal of cancer.

[168]  Zhengping Hu,et al.  Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[169]  Jean-Christophe Leroux,et al.  Disulfide-containing parenteral delivery systems and their redox-biological fate. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[170]  S. Ganta,et al.  A review of stimuli-responsive nanocarriers for drug and gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[171]  D. Mager,et al.  Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia , 2012, Pharmaceutical Research.

[172]  A. Safavy,et al.  Synthesis of bombesin analogues for radiolabeling with rhenium‐188 , 1997, Cancer.

[173]  P. Soon-Shiong,et al.  SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. , 2009, Translational oncology.

[174]  I. Kwon,et al.  Stable paclitaxel formulations in oily contrast medium. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[175]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[176]  Gwan Sun Lee,et al.  Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. , 2006, Journal of separation science.

[177]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[178]  V. Ling,et al.  Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. , 1998, Cancer research.

[179]  Deep Pooja,et al.  Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. , 2014, Colloids and surfaces. B, Biointerfaces.

[180]  P. Alken,et al.  Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer , 2009 .

[181]  R. Straubinger,et al.  Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes , 1994, Pharmaceutical Research.

[182]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[183]  Qiang Zhang,et al.  Development of liposomal formulations: From concept to clinical investigations , 2013 .

[184]  T. Yoshikawa,et al.  Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer , 2012, Investigational New Drugs.

[185]  J Moan,et al.  Interaction of cremophor EL with human plasma. , 1991, International Journal of Biochemistry.

[186]  C. J. Lee,et al.  Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[187]  T. Fojo,et al.  Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[188]  S. Balasubramanian,et al.  Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. , 1994, Biochemistry.

[189]  N. Saijo,et al.  Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities , 1995, Japanese journal of cancer research : Gann.

[190]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[191]  Xuelian Xu,et al.  Self-assembled Micelle Loading Cabazitaxel for therapy of Lung Cancer. , 2016, International journal of pharmaceutics.

[192]  M. ElSayed,et al.  Formulation of Acid-Sensitive Micelles for Delivery of Cabazitaxel into Prostate Cancer Cells. , 2016, Molecular pharmaceutics.

[193]  R. P. Garay,et al.  Immunogenicity of Polyethylene Glycol (PEG) , 2011 .

[194]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.